Although copay adjustment programs might encourage patients to look for cheaper therapeutic alternatives before turning to a more expensive treatment, they can be problematic for individuals whose plans involve high cost-sharing or co-insurance.
Lawmakers who disagree on other aspects of health policy often find common ground when it comes to prescription drugs. So where are state proposals on these issues landing for the 2022 session?
